Lupin and Glenmark Pharma Report Declines in Q2FY27 Profits Amid Market Challenges
Lupin and Glenmark Pharmaceuticals reported significant declines in their Q2FY27 consolidated net profits, falling 22.19% to Rs 1,155.3 crore and 56.8% to Rs 263.8 crore respectively. Lupin's revenue rose to Rs 7,827.3 crore, while Glenmark's revenue dropped to Rs 4,247.3 crore. Both companies cited exceptional items and challenges in the US market, including settlements related to antitrust matters and increased competition, impacting their earnings during the quarter.
First-hand measurement across 9 sources
We measured how 9 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (50/100). Lens Score 37/100.
Outlets measured: freepressjournal, businessstandard, news18, freepressjournal, businessstandard, thefinancialexpress, english, mint, and 1 more. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (48–62/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 3 Nov, 09:00 pm. Other outlets followed.